516 Peripheral and tumoral immune activity in the expansion part of the first-in-human DuoBody®-PD-L1×4–1BB (GEN1046) trial

Схожие документы

• 516 Peripheral and tumoral immune activity in the expansion part of the first-in-human DuoBody®-PD-L1×4–1BB (GEN1046) trial
  по: Andrés Cervantes, и др.
  Опубликовано: (2021-11-01)
• 561 DuoBody®-PD-L1×4–1BB (GEN1046) induces superior immune-cell activation, cytokine production and cytotoxicity by combining PD-L1 blockade with conditional 4–1BB co-stimulation
  по: Maria Jure-Kunkel, и др.
  Опубликовано: (2020-11-01)
• 412 First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1×4–1BB (GEN1046) in patients with advanced solid tumors
  по: Ignacio Melero, и др.
  Опубликовано: (2020-11-01)
• DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity
  по: Maria Jure-Kunkel, и др.
  Опубликовано: (2022-06-01)
• 493 First-in-human phase 1/2 trial to evaluate the safety and initial clinical activity of DuoBody®-CD40×4–1BB (GEN1042) in patients with advanced solid tumors
  по: Homer Adams, и др.
  Опубликовано: (2021-11-01)